EUVIMEDEUVIMED entdecken
Crossref

Effects of the anti-inflammatory drug celecoxib on cell death signaling in human colon cancer

Ryuto Maruyama, Yuki Kiyohara, Yasuhiro Kudo, Tomoyasu Sugiyama

Naunyn-Schmiedeberg's Archives of Pharmacology · 2023

DOI: 10.1007/s00210-023-02399-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2023. Verfasst von Ryuto Maruyama und 3 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Bionics, Tokyo University of Technology, 1401-1 Katakura-Machi, Tokyo, Hachioji, 192-0982, Japan. maruyamart@stf.teu.ac.jp. Hauptthemen laut MEDLINE: Sulfonamides, Colonic Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: Tokyo University of Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The anti-inflammatory drug celecoxib, the only inhibitor of cyclooxygenase-2 (COX-2) with anticancer activity, is used to treat rheumatoid arthritis and can cause endoplasmic reticulum (ER) stress by inhibiting sarco/ER Ca2 +-ATPase activity in cancer cells. This study aimed to investigate the correlation between celecoxib-induced ER stress and the effects of celecoxib against cell death signaling. Treatment of human colon cancer HCT116 cells with celecoxib reduced their viability and resulted in a loss of mitochondrial membrane potential ([Formula: see text]). Additionally, celecoxib treatment reduced the expression of genes involved in mitochondrial biogenesis and metabolism such as mitochondrial transcription factor A (TFAM) and uncoupling protein 2 (UCP2). Furthermore, celecoxib reduced transmembrane protein 117 (TMEM117), and RNAi-mediated knockdown of TMEM117 reduced TFAM and UCP2 expressions. These results suggest that celecoxib treatment results in the loss of [Formula: see text] by reducing TMEM117 expression and provide insights for the development of novel drugs through TMEM117 expression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SulfonamidesColonic NeoplasmsHumansCelecoxibPyrazolesCyclooxygenase 2 InhibitorsAnti-Inflammatory AgentsCell DeathApoptosis

Stichwörter der Autor:innen

CelecoxibEndoplasmic reticulum stressMitochondrial membrane potentialMitochondrial transcription factor ATransmembrane protein 117Uncoupling protein 2

Substanzen

CelecoxibSulfonamidesPyrazolesCyclooxygenase 2 InhibitorsAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Graduate School of Bionics, Tokyo University of Technology, 1401-1 Katakura-Machi, Tokyo, Hachioji, 192-0982, Japan. maruyamart@stf.teu.ac.jp.
  • Graduate School of Bionics, Tokyo University of Technology, 1401-1 Katakura-Machi, Tokyo, Hachioji, 192-0982, Japan.

Förderung

  • Tokyo University of Technology

Zitieren

APA

Maruyama, R., Kiyohara, Y., Kudo, Y., & Sugiyama, T. (2023). Effects of the anti-inflammatory drug celecoxib on cell death signaling in human colon cancer. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-023-02399-4

Vancouver

Maruyama R, Kiyohara Y, Kudo Y, Sugiyama T. Effects of the anti-inflammatory drug celecoxib on cell death signaling in human colon cancer. Naunyn-Schmiedeberg's Archives of Pharmacology. 2023. doi:10.1007/s00210-023-02399-4

BibTeX
@article{Maruyama2023,
  author = {Maruyama, Ryuto and Kiyohara, Yuki and Kudo, Yasuhiro and Sugiyama, Tomoyasu},
  title = {Effects of the anti-inflammatory drug celecoxib on cell death signaling in human colon cancer},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2023},
  doi = {10.1007/s00210-023-02399-4}
}
Kostenlos starten →